Navigation Links
iBio Pharmaceutical Technology Embraced by the Government of Brazil
Date:6/24/2013

p>"The production process from the extraction plant is a novelty in the country. The technology ensures higher security than the biological produced from viruses and bacteria. It produces fewer side effects and less resistance facing the human body which receives the treatment. Moreover, it requires less investment."

"Ceara is very happy to help correct regional inequalities. It is the country's time to celebrate because we see investing in Brazil and seeing possibilities," said state governor Cid Gomes.

"Organic products are more effective compared to traditional medicines from chemical synthesis, increasing the chances of successful treatment especially for chronic diseases. They are made from living material and manufactured from processes involving personalized medicine and molecular biology."

"Currently biological resources represent 43% of the medicines used by the Ministry of Health, or about U.S. $ 4 billion per year."

Full text of the original Portuguese language article is available at this link: http://www.jornaldebrasilia.com.br/site/noticia.php?brasil-amplia-producao-de-medicamentos-biologicos&id=476955

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform.  The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.  The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantl
'/>"/>

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
2. Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
3. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
4. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry
5. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market
6. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
7. BioConvergence® Launches New Blog Aimed at Exploring Best Practices of Pharmaceutical and Biotechnology Industries
8. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
9. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
10. GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results
11. Ohr Pharmaceutical to Present at the Marcum MicroCap Conference on May 30th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... BURLINGTON, Mass. , July 30, 2014 /PRNewswire/ ... surveyed pharmacy and medical directors in ... key drivers of biosimilar market penetration will be ... care organizations (MCOs) and the expected lower cost ... strategies for biosimilars that meet their pricing expectations ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Contributed by Jeff Wilson, and Andrew Segal, M.D., Genitrix, LLC, ... Introduction , ... recently become a popular choice as a reporter gene. GFP can be ... and to track the expression, localization, , and ...
... Helen Chun, Milhan Telatar and Richard A. Gatti,Department ... , Introduction ... (PTT) is a method used to screen large coding , ... gene responsible , for the autosomal ...
... Gita Ohlsson and Marianne Schwartz, Department of Clinical Genetics, , ... Denmark, , ... Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency , ... 21-hydroxylase. , In addition to deletions, approximately 20 ...
Cached Biology Technology:Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 2Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 3Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 4Protein Truncation Tests Using the DCode System 2Protein Truncation Tests Using the DCode System 3Detection of Mutations in the CYP21 Gene Using the DCode System 2Detection of Mutations in the CYP21 Gene Using the DCode System 3Detection of Mutations in the CYP21 Gene Using the DCode System 4Detection of Mutations in the CYP21 Gene Using the DCode System 5
(Date:7/30/2014)... University Professor Steven Chown has been awarded the ... for Excellence in Antarctic Research. , SCAR, an ... high quality international scientific research in the Antarctic ... region in the Earth system. The organisation also ... Treaty System, responsible for governing the region. , ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... 30, 2014 The Nano-Bio Manufacturing Consortium ... Air Force Research Laboratory (AFRL), has awarded funding ... University to develop electronics and biometric ... $425,000 project, with contributions from the University of ... Inc. ( Endicott, N.Y. ), is ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: